An evidence-based atlas mapping body systems → pathophysiology → biomarker signatures → targeted therapeutics. Four distinct endotypes explain the heterogeneity of Long COVID and guide treatment selection.
Long COVID is not one disease. Patients cluster into four endotypes, each with characteristic symptoms, biomarkers, and therapeutic implications.
Biomarker: Viral RNA or spike antigen persists in tissue reservoirs (gut epithelium, lymphoid tissue). Gut-predominant symptoms, inflammatory markers elevated.
Clinical hallmark: Relapsing course with viral-like episodes. GI symptoms prominent. Improved with antivirals in case series.
Biomarker: GPCR autoantibodies (β-adrenergic, muscarinic, angiotensin-1 receptor). Prominent dysautonomia and relapsing flares.
Clinical hallmark: Orthostatic intolerance, palpitations, anxiety. Responds to apheresis and B-cell targeting in case reports.
Biomarker: Acylcarnitine accumulation, abnormal two-day CPET with ventilatory threshold collapse. Post-exertional malaise is severe and reproducible.
Clinical hallmark: Exercise intolerance, brain fog, fatigue. Heavy overlap with ME/CFS. Harmed by graded exercise therapy.
Biomarker: Microclot burden, impaired endothelial function, exertional desaturation with normal resting tests. ADMA elevated, arginine low.
Clinical hallmark: Breathlessness on exertion, chest tightness, cold extremities. Responds to anticoagulation and vasodilators in observational data.
Five core pathophysiological processes that underlie Long COVID. Many patients have multiple mechanisms; identifying which dominate guides therapy.
SARS-CoV-2 RNA detected in gut epithelium, lymphoid tissue, and bone marrow months to years post-infection. Provides a continuous immune stimulus. Sits upstream of both immune dysregulation and secondary microclot formation.
Impaired fatty acid oxidation, reduced TCA cycle flux, early lactate accumulation. The most reproducible metabolomic finding in exertion-intolerant patients. Directly linked to post-exertional malaise.
Fibrinaloid microclots resistant to fibrinolysis, platelet hyperactivation, reduced red cell deformability. Impairs capillary perfusion and oxygen offloading. Standard coagulation panels are normal — this requires specialized assays.
Reduced short-chain fatty acid producers, increased permeability, tryptophan diverted from serotonin toward kynurenine. Peripheral serotonin depletion links gut antigen persistence to cognitive and mood symptoms via the vagus nerve.
T-cell exhaustion, altered monocyte populations, latent herpesvirus reactivation (EBV, CMV, HHV6), and GPCR-targeting autoantibodies. Drives both autoimmune symptoms and secondary metabolic dysfunction.
Long COVID touches multiple organ systems. Each shows a characteristic metabolite signature and responds to different therapeutic strategies.
| Body System | Key Biomarker Changes | Clinical Correlates | Implicated Mechanisms |
|---|---|---|---|
| Skeletal Muscle | ↑ Acylcarnitines ↓ TCA flux |
Post-exertional malaise, exercise intolerance | Bioenergetic failure, Microclots |
| Gut & Microbiome | ↓ Serotonin ↓ Butyrate |
Altered bowel habits, bloating, food intolerance | Viral persistence, Dysbiosis |
| Blood & Coagulation | Microclots ↓ RBC deformability |
Exertional breathlessness, cold extremities | Microclots, Endotheliopathy |
| Brain & Brainstem | ↑ Kynurenine ↑ Quinolinic acid |
Cognitive slowing, unrefreshing sleep, dysautonomia | Dysbiosis, Neuroinflammation |
| Heart & Endothelium | ↓ Arginine ↑ ADMA |
Palpitations, chest tightness, orthostatic intolerance | Endothelial dysfunction |
| Lungs | ↑ Lactate Impaired gas exchange |
Breathlessness on exertion, air hunger | Microclots, Vascular mismatch |
| Lymphoid Tissue | Spike antigen, HERV reactivation | Tender lymph nodes, sore throat, flu-like relapses | Viral persistence, Immune dysregulation |
| Liver & Bile Acids | ↓ Bile acids ↑ Sphingolipids |
Alcohol intolerance, post-prandial fatigue | Dysbiosis, Metabolic remodelling |
On the Candidate Therapeutics page, every therapy carries an evidence tier. Here's what each tier means:
≥1 positive Phase 3 RCT in Long COVID or directly comparable post-acute infection syndrome. Confident recommendation.
Open-label pilot or case series with positive signal. Mechanistically sound. Warrants controlled trial.
Plausible mechanism but minimal clinical data. May help; lacks trial evidence. Experimental.
Mixed or null trial results. Mechanism plausible. Benefit unclear. Subset analysis may show benefit.
Target engagement shown but no clinical outcome data. Theoretical promise. Preclinical or early-phase.
In vitro or animal data only. No human trials. Very early stage. Do not infer human efficacy.